Canaccord Genuity Reaffirms Buy Rating on Compass Therapeutics
Canaccord Genuity has reaffirmed its Buy rating on Compass Therapeutics following the publication of positive Phase 2/3 clinical trial results.
Stocks · News reference
Canaccord Genuity Initiates Coverage on Kimberly-Clark With Hold Rating
Canaccord Genuity has initiated research coverage on Kimberly-Clark Corporation with a Hold rating and a $105 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Canaccord Genuity Upgrades Eldorado Gold to Buy
Canaccord Genuity has upgraded its rating for Eldorado Gold Corporation to Buy from Hold, setting a price target of CA$57.
Canaccord Genuity Initiates Coverage on CleanSpark
Canaccord Genuity has initiated coverage on CleanSpark with a Buy rating and a $20 price target.